A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 38/19 (2006.01) C07K 14/705 (2006.01) C07K 16/28 (2006.01) C12N 5/06 (2006.01) C12N 5/08 (2006.01) G01N 33/554 (2006.01) G01N 33/577 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2243531
Activation by CD40 ligand of renal cells bearing CD40 on the cell surface is inhibited, both in vivo and ex vivo, with an agent capable of inhibiting interaction between CD40 ligand and CD40 on the cells. Inflammatory kidney diseases are treated.
L'activation, par le ligand de CD40, de cellules rénales porteuses de la molécule CD40 sur leur surface cellulaire est inhibée, tant in vivo qu'ex vivo, grâce à un agent capable d'empêcher toute interaction entre le ligand de CD40 et la molécule CD40 se trouvant sur les cellules. On traite ainsi des affections rénales inflammatoires.
Chess Leonard
Karpusas Mihail N.
Lederman Seth
Thomas David W.
Yellin Michael J.
Biogen Incorporated
Smart & Biggar
The Trustees Of Columbia University In The City Of New York
LandOfFree
Therapeutic applications of t-bam (cd40-l) technology to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic applications of t-bam (cd40-l) technology to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic applications of t-bam (cd40-l) technology to... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1502809